ClinicalTrials.gg
Active, not recruitingNCT06650735Updated Oct 21, 2024

Bilateral Lateral Rectus Recession Versus Bilateral Primary Medial Rectus Resection in Intermittent Exotropia

An interventional study of BMR resection and BLR recession in Intermittent Exotropia, sponsored by Cairo University. Active, not recruiting at 1 site in Egypt. Open to participants aged 5 Years to 30 Years. Per ClinicalTrials.gov, last updated 2024-10-21.

Sponsored by Cairo University · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Nov 2024, 2 years ago, but the record still lists the study as active, not recruiting.
  • Registered 1 year 3 months after the study started (first participant enrolled Jul 2023, registered Oct 2024).
Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
5 Years to 30 Years
Sex
All
01

Study summary

The goal of this clinical trial is to compare the efficacy of bilateral lateral rectus recession and bilateral primary medial rectus resection in basic type intermittent exotropia

Participants will be randomized into two groups: bilateral lateral rectus (BLR) recession and bilateral medial rectus (BMR) resection groups then followed up in the clinic for 6 months to compare motor alignment and sensory functions

Read the detailed description

Study location: Cairo university hospitals

Methodology:

Patients with basic type intermittent exotropia who are indicated to undergo surgical intervention will be grouped into two groups one group will undergo bilateral lateral rectus recession and the other will undergo bilateral medial rectus resection.

  • Preoperatively, all patients will be subjected to:

    1. A detailed history taking including presence of asthenopia, monocular closure, disfigurement or diplopia. The previous use of glasses for optical correction, use of minus lenses, or prior part time occlusion will be documented.
    2. A detailed ophthalmological examination; including uncorrected and best corrected visual acuity whenever possible, cycloplegic refraction, anterior segment examination and dilated fundus examination.
    3. Motor Evaluation:

      • Ductions and versions will be done to assess the ocular motility in 9 positions of gaze.
      • The angle of deviation will be measured by the alternate prism cover test for both distance (6 meters) and near (33 cm) , with and without glasses.
      • The angles of misalignment will also be measured in side gazes and in straight up and down gaze whenever possible.
      • In patients with near-far disparity, the angle of deviation will be measured again after patching one eye for 30 minutes, as well as after putting +3 D lenses in front of each eye.

      Patients with near-far disparity >10 prism diopters (PD) will not be included

    4. Sensory Evaluation:

      Worth 4 dot test and stereopsis using Random dot test (when possible) The control of exotropia will be assessed using both the newcastle control score

      Patients will be randomly assigned to either surgery using simple randomization by random number generator

  • Intervention:

    • One group will undergo bilateral lateral rectus recession and the other will undergo bilateral medial rectus resection according to the standard tables.
    • All cases will be done under general anaesthesia.
    • Both surgeries take about 30 minutes.
    • Postoperative treatment combined tobramycin 0.3% and dexamethasone 0.1% eye drops 3 times daily and the same combination eye ointment at night for 3 weeks.
    • Postoperative follow up will be 1 week, 6 weeks, 3 months and 6 months (minimum follow up)
  • Postoperative assessment:

    • Extraocular movement in lateral gazes will be examined for comitance
    • Alignment in the primary position will be assessed and any deviation will be measured using alternate prism cover test
    • Palpebral fissure height will be measured
    • Worth 4 dot test and stereopsis will be assessed (when possible)

      • In cases of failure either over correction or under correction reoperation will be performed after 3 months of the initial surgery.
  • Sample size

We are planning a study of the difference in the postoperative angle between the 2 surgical techniques. Assuming a mean difference of 5 PD with a standard deviation of 5 PD, an alpha error of 0.05 and a power of study of 0.8, a total of 17 subjects were found to be needed in each group. Assuming a drop-out rate of 20%, a sample of 20 subjects will be targeted in each group.

02

Conditions studied

  • Intermittent Exotropia

Browse trials for

Keywords

  • IXT
  • lateral rectus recession
  • medial rectus resection
03

In context

Exotropia

58 studies on the registry are indexed under Exotropia; 13 are open to participants now.

This study's planned enrollment of 40 is below the median of 50 across 49 interventional studies indexed under Exotropia.

Browse Exotropia studies →

Lead sponsor

Cairo University is the lead sponsor of 4,941 studies on the registry; 1,458 are open to participants now.

Of its 37 completed or terminated interventional studies of FDA-regulated products, 5 (14%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
5 Years to 30 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with basic type intermittent exotropia
  • Measurable angle 25-40 prism diopters

Exclusion criteria

Exclusion Criteria:

  • Restrictive or paralytic deviation or if forced duction test is positive on horizontal muscles
  • Incomitant deviation, vertical or oblique muscles surgery and significant A or V pattern
  • Previous strabismus, orbital or buckle surgery
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Investigator, Outcomes assessor)
Enrollment
40 participants (estimated)

Study arms

  • Active comparator
    BMR resection

    Bilateral medial rectus muscle resection

    Procedure: BMR resection

  • Active comparator
    BLR recession

    Bilateral lateral rectus muscle recession

    Procedure: BLR recession

Interventions

  • ProcedureBMR resection

    Lid speculum will be applied. Fornix conjunctival incision will be used to expose medial rectus muscle. Area that will be resected will be marked using calipers. Double-armed polyglactin 910 suture (6/0 Vicryl) will be used in securing the muscle. The muscle then excised anterior to the sutures and the stump cut flush to the sclera. The muscle will be sutured again to the original insertion by scleral sutures which will be tied together. Conjunctiva will be closed using polyglactin 910 suture (6/0 Vicryl).

  • ProcedureBLR recession

    Lid speculum will be applied. Fornix conjunctival incision will be used to expose lateral rectus muscle. Double-armed polyglactin 910 suture (6/0 Vicryl) will be used in securing the muscle close to the insertion. The muscle will then be cut anterior to the sutures flush with the sclera. Calipers will used to mark the new insertion on sclera measured from the stump. The muscle will be sutured again to the new insertion by scleral sutures, which will be tied together. Conjunctiva will be closed using polyglactin 910 suture (6/0 Vicryl).

06

What researchers measure

Primary outcomes

  1. Motor alignment in primary position

    Success rate defined as orthophoria between exotropia/phoria ≤ to 8 prism diopters \& esotropia/phoria ≤ 4 prism diopters

    Time frame: 12 months

Secondary outcomes

  1. Palpebral fissure height

    Change in palpebral fissure height in mm

    Time frame: 12 months

  2. Lateral gaze comitance/incomitance

    Difference between angles of deviation in right gaze, primary position, and left gaze

    Time frame: 12 months

  3. Stereopsis

    Change in stereoacuity in log seconds of arc

    Time frame: 12 months

07

Study locations

1 site
08

References and documents

Publications

  • Choi MY, Hwang JM. The long-term result of slanted medial rectus resection in exotropia of the convergence insufficiency type. Eye (Lond). 2006 Nov;20(11):1279-83. doi: 10.1038/sj.eye.6702095. Epub 2005 Sep 9. PubMed 16151478 ↗
  • Wang X, Zhang W, Chen B, Liao M, Liu L. Comparison of bilateral medial rectus plication and resection for the treatment of convergence insufficiency-type intermittent exotropia. Acta Ophthalmol. 2019 May;97(3):e448-e453. doi: 10.1111/aos.14056. Epub 2019 Feb 11. PubMed 30740923 ↗
  • Kushner BJ. Selective surgery for intermittent exotropia based on distance/near differences. Arch Ophthalmol. 1998 Mar;116(3):324-8. doi: 10.1001/archopht.116.3.324. Erratum In: Arch Ophthalmol 1998 Jun;116(6):834. PubMed 9514485 ↗
  • Pediatric Eye Disease Investigator Group; Writing Committee; Donahue SP, Chandler DL, Holmes JM, Arthur BW, Paysse EA, Wallace DK, Petersen DB, Melia BM, Kraker RT, Miller AM. A Randomized Trial Comparing Bilateral Lateral Rectus Recession versus Unilateral Recess and Resect for Basic-Type Intermittent Exotropia. Ophthalmology. 2019 Feb;126(2):305-317. doi: 10.1016/j.ophtha.2018.08.034. Epub 2018 Sep 3. PubMed 30189281 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2023 (actual). Primary completion is estimated for Nov 2024, 16 months after the start.

Of 29 interventional studies with no phase under Exotropia, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 46. This study's planned 16 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 18, 2024
First posted
Oct 21, 2024
StartActual
Jul 1, 2023
Primary completionEst.
Nov 2024
CompletionEst.
Nov 2024
Last update
Oct 21, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 21, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06650735
Lead sponsor
Cairo University
Responsible party
Ahmed Awadein (Professor, Cairo University) — Principal investigator
First posted
Oct 21, 2024
Start date
Jul 1, 2023
Primary completion
Nov 2024 (estimated)
Completion
Nov 2024 (estimated)
Last update
Oct 21, 2024

Study contacts

Yehia Salah Eldeen Mostafa, MD
study chair · Cairo University

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion